[
  {
    "ts": null,
    "headline": "Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story",
    "summary": "Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre continuous glucose monitors. Inspectors identified deficiencies in Abbott’s ongoing monitoring processes, leading the company to start corrective actions and share updates with the FDA. The letter centers on quality controls for a key diabetes device line that is widely used by patients and closely watched by regulators and investors. For investors, this puts a spotlight...",
    "url": "https://finnhub.io/api/news?id=5a0d88504d241e4b9bf2cc53f18a0967c2fa981f0bf99978497baeca9d57ac4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770153068,
      "headline": "Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story",
      "id": 138347219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre continuous glucose monitors. Inspectors identified deficiencies in Abbott’s ongoing monitoring processes, leading the company to start corrective actions and share updates with the FDA. The letter centers on quality controls for a key diabetes device line that is widely used by patients and closely watched by regulators and investors. For investors, this puts a spotlight...",
      "url": "https://finnhub.io/api/news?id=5a0d88504d241e4b9bf2cc53f18a0967c2fa981f0bf99978497baeca9d57ac4d"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions",
    "summary": "Medical device leaders counter tariff pressures with innovation, as AI adoption and aging demographics support long-term growth.",
    "url": "https://finnhub.io/api/news?id=074ef44b244ed393a78b855792b4046a0d6f9db9ccf81ba909a3e639cd7c440c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138120,
      "headline": "Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions",
      "id": 138345652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Medical device leaders counter tariff pressures with innovation, as AI adoption and aging demographics support long-term growth.",
      "url": "https://finnhub.io/api/news?id=074ef44b244ed393a78b855792b4046a0d6f9db9ccf81ba909a3e639cd7c440c"
    }
  },
  {
    "ts": null,
    "headline": "Silver Economy Boom: Investing in Healthcare's Aging Tailwinds",
    "summary": "An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.",
    "url": "https://finnhub.io/api/news?id=86913971a38664fa1f8c01de5e87a4832c1200b2daafc58749a3c5d3986040d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770135480,
      "headline": "Silver Economy Boom: Investing in Healthcare's Aging Tailwinds",
      "id": 138344914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.",
      "url": "https://finnhub.io/api/news?id=86913971a38664fa1f8c01de5e87a4832c1200b2daafc58749a3c5d3986040d2"
    }
  },
  {
    "ts": null,
    "headline": "Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure",
    "summary": "Abbott Laboratories (NYSE:ABT) is included among the Dividend Growth Stocks: 25 Aristocrats. A Reuters report said Abbott Laboratories (NYSE:ABT) warned that its current-quarter profit would come in below expectations after the company also fell short of Wall Street’s revenue forecasts on January 22. Pressure has been building in Abbott’s pediatric nutrition business, which has struggled […]",
    "url": "https://finnhub.io/api/news?id=f056c6b196284ec6671f8bd618b09076190698b0038b6e24b5d11f670c81c5c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770128407,
      "headline": "Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure",
      "id": 138342660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is included among the Dividend Growth Stocks: 25 Aristocrats. A Reuters report said Abbott Laboratories (NYSE:ABT) warned that its current-quarter profit would come in below expectations after the company also fell short of Wall Street’s revenue forecasts on January 22. Pressure has been building in Abbott’s pediatric nutrition business, which has struggled […]",
      "url": "https://finnhub.io/api/news?id=f056c6b196284ec6671f8bd618b09076190698b0038b6e24b5d11f670c81c5c8"
    }
  },
  {
    "ts": null,
    "headline": "Abbott receives FDA warning letter over Freestyle Libre CGMs",
    "summary": "Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.",
    "url": "https://finnhub.io/api/news?id=9fb91f75a6109123315c860febbb9b2587109bcf6eb1f8dd3abff827a18c70b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127818,
      "headline": "Abbott receives FDA warning letter over Freestyle Libre CGMs",
      "id": 138345654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.",
      "url": "https://finnhub.io/api/news?id=9fb91f75a6109123315c860febbb9b2587109bcf6eb1f8dd3abff827a18c70b3"
    }
  },
  {
    "ts": null,
    "headline": "Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium",
    "summary": "HAYWARD, Calif., February 03, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated with Abbott’s EnSiteX™ 3D Mapping System at the 31st Annual AF Symposium 2026 meeting, being held February 5-7 in B",
    "url": "https://finnhub.io/api/news?id=0390cd2f3b142a4986da2046c6d9907f6d0fca516ed76ef9a72c7fea21394c7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120000,
      "headline": "Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium",
      "id": 138341701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "HAYWARD, Calif., February 03, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated with Abbott’s EnSiteX™ 3D Mapping System at the 31st Annual AF Symposium 2026 meeting, being held February 5-7 in B",
      "url": "https://finnhub.io/api/news?id=0390cd2f3b142a4986da2046c6d9907f6d0fca516ed76ef9a72c7fea21394c7e"
    }
  },
  {
    "ts": null,
    "headline": "4 Medical Product Stocks to Watch From a Challenging Industry (Revised)",
    "summary": "The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.",
    "url": "https://finnhub.io/api/news?id=6a5cb66c5afe5a21fb02f8dd0209293dfd7f880330f8a8712ba4e78d03be9d7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770115020,
      "headline": "4 Medical Product Stocks to Watch From a Challenging Industry (Revised)",
      "id": 138340783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.",
      "url": "https://finnhub.io/api/news?id=6a5cb66c5afe5a21fb02f8dd0209293dfd7f880330f8a8712ba4e78d03be9d7a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs CEO makes $2M bet as stock sinks",
    "summary": "Abbott Laboratories’ stock took a direct hit, wiping out nearly 10% of its market value following its Q4 earnings. Response? The CEO bought $2 million shares. Robert B. Ford, CEO of Abbott Laboratories, spent his own personal capital to buy his own company’s shares on the open market. A straight ...",
    "url": "https://finnhub.io/api/news?id=f4ce5df20e3e653828d2a12527cfa40ab715defdecee9cdc59ac0a58a36d71e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770087780,
      "headline": "Abbott Labs CEO makes $2M bet as stock sinks",
      "id": 138338544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories’ stock took a direct hit, wiping out nearly 10% of its market value following its Q4 earnings. Response? The CEO bought $2 million shares. Robert B. Ford, CEO of Abbott Laboratories, spent his own personal capital to buy his own company’s shares on the open market. A straight ...",
      "url": "https://finnhub.io/api/news?id=f4ce5df20e3e653828d2a12527cfa40ab715defdecee9cdc59ac0a58a36d71e3"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Abbott Laboratories on R. Dennis’s SubstackR. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on ABT. Abbott Laboratories’s share was trading at $106.09 as of January 29th. ABT’s trailing and forward P/E were 28.52 and 18.69 respectively according to Yahoo Finance. Abbott Laboratories, together with its […]",
    "url": "https://finnhub.io/api/news?id=a8e4e76596f2e8628340708e204c7679283d6bd3daabdd932e25195ea8b007e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770082965,
      "headline": "Abbott Laboratories (ABT): A Bull Case Theory",
      "id": 138338011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Abbott Laboratories on R. Dennis’s SubstackR. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on ABT. Abbott Laboratories’s share was trading at $106.09 as of January 29th. ABT’s trailing and forward P/E were 28.52 and 18.69 respectively according to Yahoo Finance. Abbott Laboratories, together with its […]",
      "url": "https://finnhub.io/api/news?id=a8e4e76596f2e8628340708e204c7679283d6bd3daabdd932e25195ea8b007e9"
    }
  }
]